MedTrace Logo

A Randomized Controlled Trial of a Water Protocol for Clients With Thin Liquid Dysphagia

NCT00616512 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2011-06-23

No results posted yet for this study

Summary

The Purpose of the GF Strong water protocol is to allow clients who have thin liquid dysphagia to drink water under certain specified conditions according to the rules of the water protocol. Water Protocols have been shown to improve client satisfaction, and hydration. We wish to assess this in a randomized, controlled fashion, and this is a pilot project to determine feasibility.

Conditions

  • Thin Liquid Dysphagia

Interventions

PROCEDURE

GF Strong Water Protocol

The Purpose of the GF Strong water protocol is to allow clients who have thin liquid dysphagia to drink water under certain specified conditions according to the rules of the water protocol.

Sponsors & Collaborators

  • B.C. Rehabilitation Foundation

    collaborator OTHER

  • University of British Columbia

    lead OTHER

Principal Investigators

  • Caren Carlaw, MA · University of British Columbia

  • Heather Finlayson, MD, FRCPC · University of British Columbia

  • Kathleen Beggs, Bse RDN · University of British Columbia

  • Andrew Travlos, MBBCh FRCPC · University of British Columbia

  • Dawn Coney, RN (CRN) · University of British Columbia

  • Tiffany Visser, MS · University of British Columbia

  • Caroline Marcoux, MS · University of British Columbia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2011-06-30
Completion
2011-06-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00616512 on ClinicalTrials.gov